Section Arrow
SLNO.NASDAQ
- Soleno Therapeutics
Quotes are at least 15-min delayed:2025/01/11 17:18 EST
Last
 43.11
-1.41 (-3.17%)
Day High 
44.08 
Prev. Close
44.52 
1-M High
48.83 
Volume 
790.43K 
Bid
41.69
Ask
44.8
Day Low
42.5 
Open
43.47 
1-M Low
43.32 
Market Cap 
1.92B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 45.57 
20-SMA 45.97 
50-SMA 51.05 
52-W High 60.92 
52-W Low 36.61 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.79/0.86
Enterprise Value
1.92B
Balance Sheet
Book Value Per Share
6.14
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CDTConduit Pharmaceuticals0.1233+0.0413+50.37%-- 
MRSNMersana Therapeutics0.72-0.58-44.62%-- 
TNXPTonix Pharmaceuticals Holding Corp.0.2787+0.0227+8.87%-- 
ZVSAZyVersa Therapeutics1.47+0.29+24.58%0PE
SANASana Biotechnology3.66-0.64-14.88%-- 
Quotes are at least 15-min delayed:2025/01/11 17:18 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet forthe treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.